Back to Search
Start Over
Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study.
- Source :
- Movement Disorders; Jun2007, Vol. 22 Issue 8, p1138-1144, 7p
- Publication Year :
- 2007
-
Abstract
- The objective of this study was to investigate tolerability and possible neurotrophic effects of growth hormone (GH) in treatment of multiple system atrophy (MSA). In this double-blind pilot study, MSA patients were randomized to recombinant human growth hormone (r-hGH, n = 22), 1 mg every second day (6 months) followed by alternating daily injections of 1 mg and 0.5 mg (6 months), or matched placebo (n = 21). Safety analysis demonstrated no obvious between-group differences. In both groups, there was progressive worsening of Unified Parkinson's Disease Rating Scale total score, which tended to be less in r-hGH-treated patients (12.9% at 6 months, 25.3% at 12 months) than in placebo (17.0% and 35.7%). Similarly, there was a trend to less worsening in Unified MSA Rating Scale total score with r-hGH (13.2% and 21.2%) than with placebo (21.1% and 36.5%). Cardiovascular reflex autonomic testing also tended to show less deterioration with r-hGH than with placebo at 12 months. However, 95% CI did not indicate treatment differences for any efficacy measures. In conclusion, r-hGH administration in MSA patients for up to 1 year appears safe and might influence disease symptoms, signs and, possibly, progression. The results support further studies utilizing higher doses in more patients. © 2007 Movement Disorder Society [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 08853185
- Volume :
- 22
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Movement Disorders
- Publication Type :
- Academic Journal
- Accession number :
- 64242625
- Full Text :
- https://doi.org/10.1002/mds.21501